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Abstract
Background: The MRP1 gene encodes the 190 kDa multidrug resistance-associated protein 1
(MRP1/ABCC1) and effluxes diverse drugs and xenobiotics. Sequence variations within this gene
might account for differences in drug response in different individuals. To facilitate association
studies of this gene with diseases and/or drug response, exons and flanking introns of MRP1 were
screened for polymorphisms in 142 DNA samples from four different populations.
Results:  Seventy-one polymorphisms, including 60 biallelic single nucleotide polymorphisms
(SNPs), ten insertions/deletions (indel) and one short tandem repeat (STR) were identified. Thirty-
four of these polymorphisms have not been previously reported. Interestingly, the STR
polymorphism at the 5' untranslated region (5'UTR) occurs at high but different frequencies in the
different populations. Frequencies of common polymorphisms in our populations were comparable
to those of similar populations in HAPMAP or Perlegen. Nucleotide diversity indices indicated that
the coding region of MRP1 may have undergone negative selection or recent population expansion.
SNPs E10/1299 G>T (R433S) and E16/2012 G>T (G671V) which occur at low frequency in only
one or two of four populations examined were predicted to be functionally deleterious and hence
are likely to be under negative selection.
Conclusion:  Through  in silico approaches, we identified two rare SNPs that are potentially
negatively selected. These SNPs may be useful for studies associating this gene with rare events
including adverse drug reactions.
Background
The development of drug resistance poses a serious limi-
tation to the effective treatment of cancer. Although sev-
eral different drug resistance mechanisms have been
described, members of the ABC transporter superfamily
have generated great interest because of their contribution
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Table 1: Primers and PCR conditions for amplifying and sequencing MRP1
Exons Primer 
Direction
Length 
(bp)
Primer Sequence (5' – 3') Amplicon 
Length(bp)
Additional Primer For Sequencing Tm
Exon 1 Forward 22 GCATTTGAAAAGTGGTCGCAGG 688 59
Reverse 20 TCCGCAGGAACTGAGTCACC
Exon 2 Forward 20 GCAGAAGACACCACATACCT 510 60
Reverse 20 AGAAGAAGGAACTTAGGGTC
Exon 3 Forward 19 GCATGGTGACCAGACAAAC 501 60
Reverse 19 CTCCAGCTGATCATTGCCT
Exon 4 Forward 21 ACGTGGTCCATTAAGAAATAG 571 61
Reverse 20 GACTTCTACACAAGCCAGAG
Exon 5 Forward 19 CCCAGCCCCAGAATGTGAT 358 58
Reverse 18 CCCCAGCCACATCTAAGC
Exon 6 Forward 22 TGTTGTATTGTGGTTGCACATG 383 60
Reverse 20 GAGCTGAGCATGTTCATTCG
Exon 7 Forward 20 TCCCTAAGTCTTTTGTATGC 574 AAGCCATTTTTCCTGCATGAC (forward) 61
Reverse 19 TACCCCATTTGGCAGAAAA
Exon 8 Forward 20 AGAGAGCTTAAGGACCTTGT 591 59
Reverse 19 TATGAGCCCACTTCAGGAC
Exon 9 Forward 19 CGTGTTCCCTATGCAATTC 602 59
Reverse 18 CCTGCCACCTAAGGTCAC
Exon 10 Forward 18 TCCTGGGCAGACAGATAG 439 61
Reverse 18 TGAACCACAGCCGGAACT
Exon 11 Forward 19 GCTTGGGAGAAAGGAGCGT 452 61
Reverse 19 TGAGTCCAACTGGCAGGCA
Exon 12 Forward 20 TAATAGACGGTGAAGTTGAG 743 ATGAAGAGCAAAGACAATCG (forward) 61
Reverse 20 AAGTAATTCTCTTGCCTCAG
Exon 13 Forward 21 GTCGTTGATTTATCCAGTTCA 523 61
Reverse 20 CTTTCTTTCAGGCATGACCA
Exon 14 Forward 20 TCTGAAATACCTTTTGTGGG 627 60
Reverse 19 GGTCAAAGCCTTGGAAAGT
Exon 15 Forward 21 TTACAAGGACAAAGCTGCTTG 475 60
Reverse 19 TGTATCTGCACCCATTGTC
Exon 16 Forward 20 GTTTAGTACAGTCTTGCCTT 463 60
Reverse 19 CCAAAATCCTGCCTTCTAG
Exon 17 Forward 21 GTGGGCCAGCTGTTGTCTCGT 441 61
Reverse 20 AGTGAGACCTGAGCCACACC
Exon 18 Forward 18 CGTATTGTGAGTCTCAAG 596 TACCCATTACCACAACTG (reverse) 61
Reverse 18 TTTTCCGACCCCTCTACC
Exon 19 Forward 18 GAGTTTTGCCCACCAGGT 462 61
Reverse 19 GGTGGTTTTCCACATTGCT
Exon 20 Forward 18 TATGCCCTTTCCCTCATG 758 61
Reverse 18 GAGCAAAGACCCACACCA
Exon 21 Forward 19 CTGGAGAGTGACATGGTGG 504 61
Reverse 20 GGGTGACCCTGAGTAAGTCA
Exon 22 Forward 20 GTTGAATAGCTAAAGGGGAG 599 61
Reverse 19 TGTAAAATGGGCACACTGG
Exon 23 Forward 20 ATGCCTGGTTCATCATTATT 514 58
Reverse 20 CTTTAGGTAACACTGGTATA
Exon 24 Forward 20 AGCGTGAGCTATTATTGTCA 727 61
Reverse 19 ACTCAATAGCAGAGTCGGT
Exon 25, 26 Forward 19 CCCATTGTGCATGTTTTGA 1442 AGATGCAGCTAAAGCAGTTC*
GTGACTGATGGGGTTTCG**
61
Reverse 20 AAAGACTGGACAAGCGTTAA
Exon 27 Forward 22 ACCTACTATGTGCTCTGAGCCC 693 61
Reverse 20 TACTGCCACAGTCCACTCCC
Exon 28 Forward 18 CGAGTCATTCCTTTTGGG 493 61
Reverse 20 GTAGGGCCAAATGTATGTTT
Exon 29 Forward 18 AAGGAGCTCTGATACCCC 405 61
Reverse 19 GGACAAATGGTCATCTGGG
Exon 30 Forward 19 CTCCCAAAGTGCTCAGATT 706 61
Reverse 19 GAAATGCTTGAACCCCAGA
Exon 31 Forward 21 TCTGAATGTAATGGAACAGTG 1677 61
Reverse 21 GGAAGAGCATCAGTAACTAAA
*reverse primer for Exon 25, **forward primer for Exon 26B
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Table 2: Frequencies of single nucleotide polymorphisms (SNPs) identified at MRP1
No.* SNP ID** Region Protein
residue
dbSNP
(rs)
Population
***
n Allele frequency 
(%)
No. SNP ID Region Protein 
residue
dbSNP (rs) Populatio
n
n Allele frequency 
(%)
CT CT
SNPu1 5'UTR/-51 C>T 5'UTR - - CH 36 100.00 0.00 SNPe4 E8/825 T>C Exon 8 Val>Val rs246221 CH 36 36.11 63.89
ML 35 98.57 1.43 ML 35 24.29 75.71
IN 35 100.00 0.00 IN 35 11.43 88.57
CAU 36 100.00 0.00 CAU 36 13.89 86.11
CT CT
SNPu2 5'UTR/-46 C>T 5'UTR - - CH 36 100.00 0.00 SNPe5 E9/1062 T>C Exon 9 Asn>Asn rs35587 CH 36 38.89 61.11
ML 35 98.57 1.43 ML 35 40.00 60.00
IN 35 100.00 0.00 IN 35 20.00 80.00
CAU 36 100.00 0.00 CAU 36 31.94 68.06
CT AG
SNPe1 E2/218 C>T Exon 2 Thr>Ile - CH 36 98.61 1.39 SNPi11 I9/8 A>G Intron 9 - rs35588 CH 36 61.11 38.89
ML 35 97.14 2.86 ML 35 60.00 40.00
IN 35 100.00 0.00 IN 35 80.00 20.00
CAU 36 100.00 0.00 CAU 36 68.06 31.94
AG AG
SNPi1 I2/26 G>A Intron 2 - rs8187843 CH 36 0.00 100.00 SNPi12 I9/79 G>A Intron 9 - - CH 36 0.00 100.00
ML 35 0.00 100.00 ML 35 0.00 100.00
IN 35 1.43 98.57 IN 35 1.43 98.57
CAU 35 7.14 92.86 CAU 36 0.00 100.00
AT GT
SNPi2 I2/-151 A>T Intron 2 - - CH 36 98.61 1.39 SNPe6 E10/1299 
G>T
Exon 10 Arg>Ser - CH 36 100.00 0.00
ML 35 100.00 0.00 ML 35 100.00 0.00
IN 35 100.00 0.00 IN 35 100.00 0.00
CAU 36 100.00 0.00 CAU 36 98.61 1.39
GT CT
SNPi3 I2/-93 G>T Intron 2 - - CH 36 100.00 0.00 SNPi13 I10/64 C>T Intron 
10
- rs28363993 CH 36 100.00 0.00
ML 35 100.00 0.00 ML 35 100.00 0.00
IN 35 98.57 1.43 IN 35 97.14 2.86
CAU 36 100.00 0.00 CAU 36 100.00 0.00
CG AC
SNPi4 I2/-33 C>G Intron 2 - - CH 36 100.00 0.00 SNPi14 I10/91 C>A Intron 
10
- - CH 36 0.00 100.00
ML 35 98.57 1.43 ML 35 1.43 98.57
IN 35 100.00 0.00 IN 35 4.29 95.71
CAU 36 100.00 0.00 CAU 36 0.00 100.00
GT CT
SNPi5 I3/-288 T>G Intron 3 - rs4148335 CH 36 2.78 97.22 SNPi15 I11/-95 T>C Intron 
11
- - CH 36 1.39 98.61
ML 34 1.47 98.53 ML 35 0.00 100.00
IN 35 15.71 84.29 IN 35 0.00 100.00
CAU 34 14.71 85.29 CAU 36 0.00 100.00
AC AG
SNPi6 I3/-196 A>C Intron 3 - rs4148336 CH 36 97.22 2.78 SNPi16 I11/-78 G>A Intron 
11
-
rs35595 CH 36 20.83 79.17B
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ML 35 98.57 1.43 ML 35 27.14 72.86
IN 35 84.29 15.71 IN 35 11.43 88.57
CAU 36 84.72 15.28 CAU 36 13.89 86.11
CT CT
SNPi7 I3/-66 T>C Intron 3 - rs4148337 CH 36 40.28 59.72 SNPi17 I11/-48 C>T Intron 
11
- rs3765129 CH 36 88.89 11.11
ML 35 44.29 55.71 ML 35 91.43 8.57
IN 35 48.57 51.43 IN 35 97.14 2.86
CAU 35 74.29 25.71 CAU 36 90.28 9.72
AG CT
SNPe2 E6/651 G>A Exon 6 Ser>Ser - CH 36 0.00 100.00 SNPi18 I12/56 C>T Intron 
12
- rs17265551 CH 35 98.57 1.43
ML 35 0.00 100.00 ML 35 98.57 1.43
IN 35 2.86 97.14 IN 35 94.29 5.71
CAU 36 0.00 100.00 CAU 36 97.22 2.78
GT CT
SNPi8 I7/31 G>T Intron 7 - rs8187850 CH 35 100.00 0.00 SNPi19 I12/-143 C>T Intron 
12
- - CH 31 100.00 0.00
ML 34 100.00 0.00 ML 35 100.00 0.00
IN 35 98.57 1.43 IN 35 98.57 1.43
CAU 36 98.61 1.39 CAU 36 98.61 1.39
AC AG
SNPi9 I7/54 C>A Intron 7 - rs903880 CH 34 1.47 98.53 SNPi20 I12/-85 G>A Intron 
12
- rs4148348 CH 36 8.33 91.67
ML 34 2.94 97.06 ML 35 4.29 95.71
IN 35 20.00 80.00 IN 35 5.71 94.29
CAU 36 13.89 86.11 CAU 36 8.33 91.67
CG AG
SNPi10 I7/64 C>G Intron 7 - rs246232 CH 34 61.76 38.24 SNPi21 I12/-37 A>G Intron 
12
- rs35604 CH 36 83.33 16.67
ML 34 72.06 27.94 ML 35 85.71 14.29
IN 35 65.71 34.29 IN 35 57.14 42.86
CAU 35 80.00 20.00 CAU 36 79.17 20.83
AG CT
SNPe3 E8/816 G>A Exon 8 Pro>Pro rs2230669 CH 36 2.78 97.22 SNPe7 E13/1684 
C>T
Exon 13 Leu>Leu rs35605 CH 36 83.33 16.67
ML 35 0.00 100.00 ML 35 85.71 14.29
IN 35 0.00 100.00 IN 35 57.14 42.86
CAU 36 0.00 100.00 CAU 36 80.56 19.44
CT CT
No. SNP ID Region Protein 
residue
dbSNP 
(rs)
Population n Allele frequency 
(%)
No. SNP ID Region Protein 
residue
dbSNP (rs) Populatio
n
n Allele frequency 
(%)
SNPe8 E13/1704 C>T Exon 13 Tyr>Tyr rs8187858 CH 36 100.00 0.00 SNPi28 I20/-31 C>T Intron 
20
- - CH 36 100.00 0.00
ML 35 100.00 0.00 ML 35 100.00 0.00
IN 35 95.71 4.29 IN 35 100.00 0.00
CAU 36 98.61 1.39 CAU 36 98.61 1.39
CG CT
SNPi22 I13/33 I13/33 Intron 
13
- - CH 36 0.00 100.00 SNPe1
7
E21/2793 
C>T
Exon 
21
Thr>Thr - CH 36 100.00 0.00
Table 2: Frequencies of single nucleotide polymorphisms (SNPs) identified at MRP1 (Continued)B
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ML 35 0.00 100.00 ML 35 100.00 0.00
IN 35 1.43 98.57 IN 35 98.57 1.43
CAU 36 0.00 100.00 CAU 36 100.00 0.00
AG CT
SNPe9 E14/1898 G>A Exon 14 Arg>Gln CH 36 0.00 100.00 SNPi29 I21/26 T>C Intron 
21
- rs11075296 CH 36 0.00 100.00
ML 35 0.00 100.00 ML 35 0.00 100.00
IN 35 0.00 100.00 IN 35 1.43 98.57
CAU 36 1.39 98.61 CAU 36 0.00 100.00
CT CT
SNPe1
0
E16/2001 C>T Exon 16 Ser>Ser rs8187863 CH 36 100.00 0.00 SNPi30 I22/62 T>C Intron 
22
- rs3887893 CH 36 58.33 41.67
ML 35 100.00 0.00 ML 35 52.86 47.14
IN 35 100.00 0.00 IN 35 47.14 52.86
CAU 36 98.61 1.39 CAU 36 43.06 56.94
CT CT
SNPe1
1
E16/2007 C>T Exon 16 Pro>Pro rs2301666 CH 36 98.61 1.39 SNPi31 I22/-43 C>T Intron 
22
- - CH 35 91.43 8.57
ML 35 100.00 0.00 ML 35 81.43 18.57
IN 35 100.00 0.00 IN 35 100.00 0.00
CAU 36 100.00 0.00 CAU 36 100.00 0.00
GT AG
SNPe1
2
E16/2012 G>T Exon 16 Gly>Val - CH 36 100.00 0.00 SNPi32 I24/211 G>A Intron 
24
- - CH 36 6.94 93.06
ML 35 100.00 0.00 ML 35 4.29 95.71
IN 35 98.57 1.43 IN 35 1.43 98.57
CAU 36 97.22 2.78 CAU 36 0.00 100.00
AG CT
SNPe1
3
E17/2168 G>A Exon 17 Arg>Gln rs4148356 CH 36 0.00 100.00 SNPi33 I25/103 C>T Intron 
25
- - CH 36 100.00 0.00
ML 35 2.86 97.14 ML 35 100.00 0.00
IN 35 0.00 100.00 IN 35 98.57 1.43
CAU 36 0.00 100.00 CAU 34 100.00 0.00
CT CT
SNPe1
4
E17/2217 C>T Exon 17 Ser>Ser - CH 36 100.00 0.00 SNPi34 I25/114 C>T Intron 
25
- - CH 36 98.61 1.39
ML 35 100.00 0.00 ML 35 100.00 0.00
IN 35 98.57 1.43 IN 35 100.00 0.00
CAU 36 100.00 0.00 CAU 34 100.00 0.00
AG AG
SNPe1
5
E17/2268 G>A Exon 17 Gly>Gly - CH 36 1.39 98.61 SNPi35 I25/146 G>A Intron 
25
- - CH 36 0.00 100.00
ML 35 0.00 100.00 ML 35 1.43 98.57
IN 35 0.00 100.00 IN 35 0.00 100.00
CAU 36 0.00 100.00 CAU 34 0.00 100.00
AG CG
SNPi23 I17/-168 A>G Intron 
17
- - CH 31 100.00 0.00 SNPi36 I26/-108 G>C Intron 
26
- - CH 36 0.00 100.00
ML 35 97.14 2.86 ML 35 0.00 100.00
IN 29 100.00 0.00 IN 35 2.86 97.14
CAU 32 98.44 1.56 CAU 35 2.86 97.14
Table 2: Frequencies of single nucleotide polymorphisms (SNPs) identified at MRP1 (Continued)B
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CG CT
SNPi24 I18/-30 G>C Intron 
18
- rs2074087 CH 36 15.28 84.72 SNPi37 I26/-9 C>T Intron 
26
- - CH 36 98.61 1.39
ML 35 12.86 87.14 ML 35 100.00 0.00
IN 35 37.14 62.86 IN 35 100.00 0.00
CAU 36 18.06 81.94 CAU 35 100.00 0.00
AG AG
SNPi25 I18/-27 G>A Intron 
18
- rs28363997 CH 36 0.00 100.00 SNPe1
8
E28/4002 
G>A
Exon 28 Ser>Ser rs2239330 CH 36 8.33 91.67
ML 35 0.00 100.00 ML 35 7.14 92.86
IN 35 1.43 98.57 IN 35 20.00 80.00
CAU 36 2.78 97.22 CAU 36 37.50 62.50
CT AG
SNPi26 I19/-175 C>T Intron 
19
- rs4148369 CH 36 91.67 8.33 SNPi38 I28/-45 G>A Intron 
28
- rs212087 CH 36 18.06 81.94
ML 35 91.43 8.57 ML 35 27.14 72.86
IN 35 81.43 18.57 IN 35 38.57 61.43
CAU 36 91.67 8.33 CAU 36 58.33 41.67
CT CT
SNPe1
6
E20/2651 C>T Exon 20 Thr>Met - CH 36 100.00 0.00 SNPi39 I29/-83 C>T Intron 
29
- - CH 36 100.00 0.00
ML 35 98.57 1.43 ML 35 100.00 0.00
IN 35 100.00 0.00 IN 35 97.14 2.86
CAU 36 100.00 0.00 CAU 36 98.61 1.39
CT CG
SNPi27 I20/-59 C>T Intron 
20
- - CH 36 100.00 0.00 SNPi40 I30/-51 G>C Intron 
30
- - CH 36 0.00 100.00
ML 35 97.14 2.86 ML 35 0.00 100.00
IN 35 100.00 0.00 IN 35 2.86 97.14
CAU 36 100.00 0.00 CAU 35 0.00 100.00
* The numbers of SNPs are defined as SNP(SNP locates the region)(In the certain region, the consequent number of the SNP). For example, SNPu1 means the SNP is located in the untranslated region (UTR) and the 
first SNP in the UTR.
** SNP ID for these SNPs are defined as (Region)/(position number)(major allele)(minor allele). Region shows whether SNP is in an exon (E) or intron (I). Position number of exonic SNP is the mRNA nucleotide 
position using the translation start site as position 1. For intronic SNP, the position in the genomic sequence is either upstream (-) of using the 5' boundary of the immediate downstream exon as position -1, or 
downstream (+) using 3' boundary of the immediate upstream exon as position 1. The same principle is employed to the indel and STR. The position is specific to the first nucleotide in the genomic sequence. 
(reference mRNA ID:NM_004996.2).
*** CH, ML, IN and CAU represent Chinese, Malay, Indian and Caucasian, respectively.
Table 2: Frequencies of single nucleotide polymorphisms (SNPs) identified at MRP1 (Continued)BMC Genomics 2006, 7:111 http://www.biomedcentral.com/1471-2164/7/111
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to multidrug resistance of tumor[1,2]. The 170 kDa P-
glycoprotein, encoded by the MDR1 gene, was the first
member of this family to be described [3]. Subsequently,
the 190-kDa multidrug resistance-associated protein-1
(MRP1/ABCC1) was isolated from a multidrug resistance
lung cancer cell line that does not express MDR1 [4]. Both
these transporters have been implicated in the resistance
of various cancers to chemotherapy. Although MRP1 is
only 18% identical to MDR1 at the amino acid level, it
transports several similar drugs as MDR1 including doxo-
rubicin, vincristine and colchicine. However, while drugs
transported by MDR1 are usually neutral or cationic,
drugs effluxed by MRP1 are anionic, frequently conju-
gated with glutathione and other anions, or are co-trans-
ported with glutathione [2]. MRP1 has also been
implicated to play important roles in cellular anti-oxida-
tive defense and inflammation [5,6].
MRP1 is located on chromosome 16 at band 13.1 and
spans approximately 200 kb. It contains 31 exons and
encodes 1531 amino acids. The MRP1 protein is predicted
to comprise three membrane spanning domains (MSDs)
and two nucleotide binding domains (NBDs) [4-7].
Genetic polymorphisms in MDR1 have been associated
with differences in MDR1 expression and function as well
as drug response and disease susceptibilities [8-10]. SNPs
within MDR1 that have been associated with functional
Table 3: Frequencies of insertion/deletions (indel) identified at MRP1
No. indel ID Region Amino acid change dbSNP (rs) Population n frequency (%)
insertion Deletion
Indel1 5'UTR/-74 14bp indel 5'UTR - - CH 36 100.00 0.00
ML 35 100.00 0.00
IN 35 97.14 2.86
CAU 36 100.00 0.00
Indel2 I2/17 G indel Intron 2 - - CH 36 0.00 100.00
ML 35 0.00 100.00
IN 35 0.00 100.00
CAU 36 1.39 98.61
Indel3 I3/-70 T indel Intron 3 - - CH 36 0.00 100.00
ML 35 0.00 100.00
IN 35 0.00 100.00
CAU 36 1.39 98.61
Indel4 I5/-25 12 bp indel Intron 5 - rs3830390 CH 36 0.00 100.00
ML 35 0.00 100.00
IN 35 1.43 98.57
CAU 36 0.00 100.00
Indel5 I12/-119 G indel Intron 12 - - CH 36 0.00 100.00
ML 35 1.43 98.57
IN 35 0.00 100.00
CAU 36 0.00 100.00
Indel6 I16/7 6bp indel Intron 16 - - CH 36 0.00 100.00
ML 35 1.43 98.57
IN 35 0.00 100.00
CAU 36 0.00 100.00
Indel7 I17/-182 5bp indel Intron 17 - - CH 30 81.70 18.30
ML 35 74.29 25.71
IN 29 86.20 13.80
CAU 30 80.00 20.00
Indel8 I18/-38 AT indel Intron 18 - - CH 36 0.00 100.00
ML 35 2.86 97.14
IN 35 0.00 100.00
CAU 36 1.39 98.61
Indel9 I24/49 C indel Intron 24 - - CH 36 0.00 100.00
ML 35 0.00 100.00
IN 35 1.43 98.57
CAU 36 0.00 100.00
Indel10 I29/-13 T indel Intron 29 - rs4148379 CH 36 45.83 54.17
ML 35 41.43 58.57
IN 35 61.43 38.57
CAU 36 75.00 25.00BMC Genomics 2006, 7:111 http://www.biomedcentral.com/1471-2164/7/111
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differences were found to demonstrate evidence of recent
positive selection [11]. However, less is known about the
polymorphisms within MRP1. Although numerous SNPs
have been identified within this gene.([12-17], most of
these studies were performed on a single population
which was primarily either Chinese, Japanese or Cauca-
sians in origin. Thus far, no association have been
observed between the few SNPs at MRP1 and functional
differences [12,17-19] possibly because neither the func-
tionally important SNP nor SNPs in LD with the func-
tional SNP were examined. These studies which examined
only a few of the many SNPs within MRP1, without
knowledge of the functional SNP nor the LD or haplotype
profile in that population may not have been powerful
enough to identify any association. Recently, we found
evidence of genomic signatures of recent positive selec-
tion in a SNP at the 5' flanking region (5'FR) of MRP1 in
a Caucasian population and demonstrated that this SNP
altered MRP1 promoter activity [20].
In the present study, we sequenced all the exons as well as
the 5' and 3' flanking regions of MRP1 to comprehen-
sively scan for polymorphisms in 142 DNA samples from
four different populations, namely, the Chinese, Malays,
Indians and Caucasians. Nucleotide diversity of the
exonic polymorphisms was determined and the func-
tional effects of the non-synonymous SNPs were pre-
dicted using three programs, SIFT, PolyPhen and
PANTHER. We found that SNPs E10/1299G>T, which
resulted in arginine-serine substitution at amino acid
position 433 (R433S) and E16/2012G>T, which resulted
in glycine-valine substitution at amino acid position 671
(G671V), may potentially adversely affect the function of
MRP1. While these two SNPs, which have low minor
allele frequencies (<3%), may not be useful for studies
associating this gene with common diseases/drug
response, it may, nonetheless, be useful for studies associ-
ating this gene with rare events including adverse drug
reactions (ADRs).
Results and discussion
Profile of polymorphisms within MRP1 in the different 
populations
De novo sequencing of approximately 18 kb of genomic
DNA at MRP1, including all the 31 exons as well as flank-
ing regions, was performed in 142 healthy individuals
from four different populations to identify polymor-
phisms at MRP1 in the different populations. A total of 71
polymorphisms were identified including 60 bi-allelic
SNPs, ten indels and one short tandem repeat (STR) (Fig-
ure 1, Tables 2, 3, 4). An examination of currently
reported SNPs in the dbSNP Build 125 database [21] and
published reports [12-17,22] revealed that 26 SNPs and 8
indels were not previously reported and hence represent
novel polymorphisms.
Nineteen of the 60 SNPs identified were found in all four
populations while 28 of these SNPs were population-spe-
cific with 22 of these population-specific SNPs occurring
only once out of 284 chromosomes examined (single-
tons). While the STR and two indels were polymorphic in
all the populations examined, the other seven indels were
population-specific of which six were singletons.
None of the indels or STR identified occurred within
exons (Fig. 1, Tables 3 and 4). Eighteen of the 60 bi-allelic
SNPs were found in exonic regions, six of which resulted
in non-synonymous change (Fig. 1, Table 2). These results
suggest that polymorphisms at MRP1 are largely conserv-
ative since less than 10% of these polymorphisms (6/71)
presented as non-synonymous changes which are poten-
tially capable of disrupting the MRP1 protein structure/
function. Nonetheless, it is possible for synonymous or
intronic SNPs to affect MRP1 expression or function
through the alteration of the mRNA transcript stability or
Table 4: Frequencies of GCC trinucleotide repeats at MRP1
Trinucleotide 
repeats
Region Amino acid 
change
dbSNP (rs) GCC repeat 
No.
frequency (%)*
CH (n = 36) ML n = (35) IN n = (35) CAU n = (36)
5'UTR/-118 
GCC repeats
5'UTR - - 7 18.57 12.50
8 1.43
9 5.56 1.43 4.29 1.39
10 1.39 4.29
11 25.00 20.00 21.43 5.56
12 9.72 5.71
13 50.00 51.43 47.14 56.94
14 4.17 10.00 5.71 19.44
15 2.78 7.14 1.43 4.17
16 1.39
* Repeat frequencies in bold represent GCC repeats that have relative frequencies (≥ 10%).BMC Genomics 2006, 7:111 http://www.biomedcentral.com/1471-2164/7/111
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folding [23] thereby affecting downstream splic-
ing[24,25], processing[26], translational control [27] or
regulation [28]. Additionally, polymorphisms at the
5'UTR/promoter and 3'UTR may influence promoter
activity and hence gene expression or mRNA transcript
stability.
Interestingly, although no polymorphisms were identified
at the 3'UTR region (exon 31), four polymorphisms,
including the STR (Table 4) and one indel (Table 3) were
found to reside at the 5'UTR/reported core promoter
region [29] of MRP1. Three of these promoter polymor-
phisms were novel but population-specific with SNPs
5'UTR/-46C>T and 5'UTR/-51C>T occurring only in the
Malay population and the polymorphism 5'UTR/-74 14
bp indel occurring only in the Indian population. Inser-
tion/deletion polymorphisms in promoter regions have
been correlated with the modulation of the expression of
genes (e.g. matrix metalloproteinase I gene [30]). It is thus
possible that the 14 bp indel polymorphism in the Indian
population may influence the promoter activity and
hence the expression of MRP1.
The STR polymorphism found at the 5'UTR/promoter
region of MRP1 is a GCC trinucleotide repeat and 7–16 of
such repeats were observed in the four populations (Table
4). The most commonly occurring GCC repeat number in
all the four populations was 13 which occurred at a fre-
quency of 50.00%, 51.43%, 47.14% and 56.94% in the
Chinese, Malay, Indian and Caucasian populations,
respectively. Eleven GCC repeats also occurred at high fre-
quencies (≥ 20%) in most of the populations except the
Distribution of polymorphisms identified in this study across MRP1 Figure 1
Distribution of polymorphisms identified in this study across MRP1. The respective positions of all the polymor-
phisms across MRP1 are displayed. Polymorphisms at this locus include 60 SNPs, ten indels and one short tandem repeat (STR). 
Polymorphisms that have not been previously reported are highlighted with asterisks.
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Table 5: Comparisons of polymorphisms identified in this study with those reported in HapMap/Perlegen
A
HAPMAP Perlegen
CHB CEPH CHB EA
# common polymorphisms 19 19 14 14
This Study # non-common 
polymorphisms
polymorphisms found 
in HapMap/Perlegen 
but not in this study
25 (22) 23 (22) 1 (0) 1 (0)
polymorphisms found 
in this study but not in 
HapMap/Perlegen
41 (26) 41 (26) 46 (28) 46 (26)
() refers to number of monomorphic SNPs in that category in that population
B
SNP ID dbSNP ID Popu N Our data N HapMap n Perlegen
I2/26 G>A rs8187843 A G A G
CH 36 0.00 100.00 45 0.00 100.00
CAU 35 7.14 92.86 60 5.83 94.17
I7/31 G>T rs8187850 G T G T
CH 35 100.00 0.00 45 100.00 0.00
CAU 36 98.61 1.39 60 100.00 0.00
I7/54 C>A rs903880 A C A C
CH 34 1.47 98.53 45 4.44 95.56
CAU 36 13.89 86.11 60 25.00 75.00
I7/64 C>G rs246232 C G C G C G
CH 34 61.76 38.24 44 55.68 44.32 21 50.00 50.00
CAU 35 80.00 20.00 60 66.67 33.33 24 52.08 47.92
E8/825 T>C rs246221 C T C T C T
CH 36 36.11 63.89 45 46.67 53.33 24 56.25 43.75
CAU 36 13.89 86.11 60 28.33 71.67 22 45.45 54.55
E9/1062 T>C rs35587 C T C T C T
CH 36 38.89 61.11 45 46.67 53.33 24 58.33 41.67
CAU 36 31.94 68.06 60 28.33 71.67 24 45.83 54.17
I11/-78 G>A rs35595 A G A G
CH 36 20.83 79.17 45 31.11 68.89
CAU 36 13.89 86.11 60 13.33 86.67
I11/-48 C>T rs3765129 C T C T C T
CH 36 88.89 11.11 45 88.89 11.11 24 93.75 6.25
CAU 36 90.28 9.72 58 85.34 14.66 24 85.42 14.58
I12/56 C>T rs17265551 C T C T C T
CH 35 98.57 1.43 45 95.56 4.44 24 97.92 2.08
CAU 36 97.22 2.78 60 90.83 9.17 24 89.58 10.42
I12/-85 G>A rs4148348 A G A G
CH 36 8.33 91.67 45 4.44 95.56
CAU 36 8.33 91.67 60 7.50 92.50
I12/-37 A>G rs35604 A G A G A G
CH 36 83.33 16.67 45 72.22 27.78 24 81.25 18.75
CAU 36 79.17 20.83 60 82.50 17.50 24 91.67 8.33
E13/1684 C>T rs35605 C T C T C T
CH 36 83.33 16.67 45 72.22 27.78 24 81.25 18.75
CAU 36 80.56 19.44 60 82.50 17.50 24 91.67 8.33
E13/1704 C>T rs8187858 C T C T C T
CH 36 100.00 0.00 45 100.00 0.00 24 100.00 0.00BMC Genomics 2006, 7:111 http://www.biomedcentral.com/1471-2164/7/111
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Caucasians. Interestingly, while seven GCC repeats
occurred at relatively high frequencies in the Indian and
Caucasian populations (≥ 12%), this number of repeats
was not observed in either the Chinese or Malay popula-
tion. These observations highlight the differences in the
distribution of the number of the MRP1 promoter GCC
repeats in the different populations with the Indians and
Caucasians being more similar to each other than to the
Chinese and Malays. The number of STR repeats residing
within or close to promoters has been found to modulate
the promoter activity of genes [31-34]. Interestingly, dif-
ferences in the CGG and GCC trinucleotide repeats at the
5'UTR/promoter region of the Fragile X mental retarda-
tion genes (FMR1 and FMR2, respectively) have been
associated with differences in the methylation status of
the promoter and expression of the genes [35]. Hence this
common polymorphism at the 5'UTR/promoter region of
MRP1 with distinctly different distribution of repeat num-
bers in the different population may have potential func-
tional significance.
Comparison of polymorphisms identified in this study with 
those reported in the HapMap and Perlegen databases
Two publicly available databases HapMap [36] and Perle-
gen [37] examined genome-wide polymorphisms (includ-
ing polymorphisms at the MRP1 gene) in several
populations. HapMap genotyped already known SNPs
from public databases at a density of approximately one
SNP per 5 kb of DNA in 4 different populations namely,
45 Japanese from Tokyo, 45 Chinese from Beijing (CHB),
60 US residents with northern and western European
ancestry by the Centre d'Etude du Polymorphisme
Humain (CEPH) and 60 Yoruba people of Ibadan (YRI).
Approximately 1.6 million SNPs from 24 Han Chinese
(CH), 24 European American (EA) and 23 African Ameri-
can (AA) were successfully genotyped in the Perlegen
project. The SNPs genotyped in the Perlegen project were
either reported in public databases or identified through
their array-based re-sequencing of 24 human samples of
diverse ancestry [38,39]. We thus compared the polymor-
phisms at the MRP1 gene that we identified through de
CAU 36 98.61 1.39 60 90.83 9.17 24 95.83 4.17
E16/2001 C>T rs8187863 C T T C T
CH 36 100.00 0.00 45 100.00 0.00 24 100.00 0.00
CAU 36 98.61 1.39 60 98.33 1.67 24 95.83 4.17
E16/2007 C>T rs2301666 C T C T C T
CH 36 98.61 1.39 45 97.78 2.22 24 97.92 2.08
CAU 36 100.00 0.00 60 100.00 0.00 24 100.00 0.00
I18/-30 G>C rs2074087 C G C G
CH 36 15.28 84.72 24 14.58 85.42
CAU 36 18.06 81.94 24 4.17 95.83
I21/26 T>C rs11075296 C T C T C T
CH 36 0.00 100.00 45 0.00 100.00 24 0.00 100.00
CAU 36 0.00 100.00 60 0.00 100.00 24 0.00 100.00
I22/62 T>C rs3887893 G A G A
CH 36 58.33 41.67 45 50.00 50.00
CAU 36 43.06 56.94 59 37.29 62.71
E28/4002 G>A rs2239330 A G A G A G
CH 36 8.33 91.67 45 11.11 88.89 24 16.67 83.33
CAU 36 37.50 62.50 60 29.17 70.83 24 31.25 68.75
I28/-45 G>A rs212087 A G A G A G
CH 36 18.06 81.94 45 20.00 80.00 24 18.75 81.25
CAU 36 58.33 41.67 60 39.17 60.83 24 43.75 56.25
C
P-value Our data HapMap Perlegen
CH EA Both CH EA Both CH EA Both
Average 
difference 
between 
datasets
Our data - - - 0.77 0.24 0.26 0.28 0.83 0.71
HapMap 0.42 2.11 1.27 - - - 0.03 0.16 0.02
Perlegen 2.54 0.83 0.85 3.48 3.57 3.67 - - -
Note: Cells in the top right triangular section indicate p values of paired-samples t test, whereas those in the lower triangular section contain the 
average differences in allele frequencies between comparable SNPs between the respective data sets.
Table 5: Comparisons of polymorphisms identified in this study with those reported in HapMap/Perlegen (Continued)BMC Genomics 2006, 7:111 http://www.biomedcentral.com/1471-2164/7/111
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novo sequencing of DNA samples from 142 individuals of
4 different populations with those reported in the HAP-
MAP and Perlegen databases. Of the populations exam-
ined in HapMap and Perlegen, only two populations,
namely the CHB and CEPH/EA, were similar to the popu-
lations that we studied. As shown in Table 5A, only 19 and
14 polymorphisms that we identified were also genotyped
in the HapMap and Perlegen projects. Curiously, 25/23
and 1/1 polymorphisms reported in HapMap and Perle-
gen, respectively, were found to be monomorphic in sim-
ilar populations that we examined. Nonetheless, all the
SNPs examined in the two databases that did not occur in
our populations were found to be either monomorphic or
of low frequency (<5%) in similar populations examined
in the two databases (Table 5A). On the other hand, 41/
41 and 46/46 polymorphisms that we identified were not
examined in either the HapMap or the Perlegen project,
respectively. While many of these polymorphisms were of
low frequencies or were monomorphic in the two popu-
lations that were similar to the HapMap/Perlegen popula-
tions, 8 of these polymorphisms were found to be of
relatively high frequencies (>5%) in at least one of the two
populations. Some of the low frequency polymorphisms
represent novel SNPs identified in this study.
Polymorphisms in our study that was also genotyped in
the HapMap and Perlegen projects were found to have
similar frequencies in similar populations (Table 5B).
Paired T-test revealed no significant difference (P > 0.05)
between allele frequencies in the respective populations
from our study and those from the HapMap or Perlegen
database (Table 5C). Interestingly, significant difference
(P < 0.05) was observed between data obtained from the
HapMap database and those from the Perlegen database
especially for the Chinese population probably due to
fewer samples being examined in the Perlegen database.
Nucleotide diversity at MRP1
The extent of variation at MRP1 was evaluated using two
conventional measures of nucleotide diversity: π, the aver-
age heterozygosity per site and θ, the population muta-
tion parameter[40]. Tajima's D statistic was also
calculated to assess deviation from the neutral mutation
model[41]. A positive Tajima's D value for a single gene is
indicative of positive heterozygote advantage while a neg-
ative Tajima's D value for an individual gene suggests
selection of a specific allele over the alternative
allele(s)[42]. However, when a negative Tajima's D value
is observed in most of the genes that were examined in a
particular population, it is suggestive of a recent expan-
sion in that population[42].
With all the exonic regions sequenced, the above nucle-
otide diversity statistics were determined for non-synony-
mous versus synonymous SNPs at MRP1 (Table 6). The θ
value for synonymous SNPs at MRP1 was found to be
16.15 × 104 (Table 6) which was comparable to mean θ
values of other reported genes including 24 transporter
genes (20.14 ± 4.10) × 104 [43], 75 candidate genes asso-
ciated with blood pressure homeostasis (15.1 ± 3.6) × 104
[44] but slightly higher than the mean θ values of 106 ran-
dom genes (10.03 ± 2.52) × 104 [45]. However, the θ value
for non-synonymous SNPs (11.73 × 104) at MRP1 was
much higher than mean θ values of the other reports (3.59
± 0.90 to 5.7 ± 1.4) × 104 [43-45] probably due to the
small size of the MRP1 exons in which the non-synony-
mous SNPs reside. Interestingly, while the π of synony-
mous SNPs (πs) at MRP1(12.62) was comparable to the
reported mean πs values in other genes (9.73 ± 4.86 to
10.67 ± 5.07) × 104 [43,45], the πns at MRP1 (0.94) was
much lower than the mean reported πns values for the
other genes (2.20 ± 1.12 to 2.75 ± 1.31) × 104 [43,45].
This low πns at MRP1 was also reported previously [43]
with the reported πns value (0.15) being much lower than
the present observation (0.94). Notably, the πns/πs  at
MRP1 was less than 1 (0.0743 in this study and 0.0110 in
the previous study [43]), suggesting that this gene is likely
to be under selective pressure. Importantly, the θ values
for both synonymous and non-synonymous SNPs were
greater than the corresponding π values, resulting in neg-
ative Tajima's D statistic which suggests that the coding
region of MRP1 may have undergone negative selection or
population expansion. It is more likely that MRP1 gene
have undergone negative selection since the average total
nucleotide diversity in the MRP1 gene (πtotal) (9.25) was
found to be greater than the amino acid diversity (πns)
(0.94) [43].
SNPs E10/1299G>T and E16/2012 G>T are potentially 
deleterious
As nucleotide diversity statistics suggest that the coding
region of MRP1 may be under negative selection, we thus
further analyzed the exonic SNPs at MRP1 to evaluate if
any of these SNPs may have deleterious effects on MRP1
structure/function.
Exonic SNPs, particularly non-synonymous SNPs, have
the potential to alter the secondary/tertiary structure of
proteins and/or affect the protein function. A total of 18
exonic SNPs were identified at this gene locus of which
five have not been previously reported (Fig. 2A, C). Most
of the exonic SNPs occurred at low frequencies (<5%) in
only one or two populations. While at least 30% of the
synonymous SNPs at MRP1 occurred at greater than 5%
frequency in all the four populations examined, all of the
non-synonymous SNPs occurred at less than 3% in only
one or at most two populations (Fig. 2C). This observa-
tion highlights the conservation of exonic polymor-
phisms at MRP1 and suggests that altering the non-
synonymous SNPs may have a deleterious effect and areBMC Genomics 2006, 7:111 http://www.biomedcentral.com/1471-2164/7/111
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Profiles of the 18 exonic SNPs in MRP1 Figure 2
Profiles of the 18 exonic SNPs in MRP1. (A) The distribution of all the exonic SNPs on the mRNA of MRP1 is presented. 
(B) The topological model of MRP1 protein secondary structure is predicted using the SOSUI program and the positions of the 
SNPs on the topological image are displayed using the TOPO2 program. Approximate locations of predicted individual trans-
membrane helices, membrane spanning domains and nucleotide binding domains are indicated as TM 1-17, MSD 1-3 and 
NBD1-2, respectively. The six nonsynonymous SNPs are highlighted in black while the 12 synonymous SNPs are colored 
green. Consensus sequences for Walker A and B are highlighted in red. The two nonsynonymous SNPs predicted by PAN-
THER to be potentially deleterious are highlighted by large black dots. (C) Table showing in silico prediction of functional signif-
icance of exonic SNPs and their frequencies in the different populations. SNPs that have previously been utilized for 
association/functional studies are also presented. For PANTHER prediction, if the subPSEC score is lower than -3.5, it can be 
interpreted that the amino acid change could have high probability of deleterious functional effect. Note: Underlined SNPs rep-
resent SNPs that have not been previously reported. * The six nonsynonymous SNPs are highlighted with single asterisks. ** 
This SNP is predicted to have effect on the function of the protein.
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mRNA of 
ABCC1
CH ML IN CAU
SNPe1* E2/218 C>T T73I 0.65 benign - 1.39 2.86 0 0
SNPe2 E6/651 G>A -- - 0 0 2 . 8 6 0
SNPe3 E8/816 G>A -- - 2.78 0 0 0 Oselin et al. 2003
SNPe4 E8/825   T>C -- - 36.11 24.29 11.43 13.89 Oselin et al. 2003
SNPe5 E9/1062  T>C -- - 38.89 40.00 20.00 31.94 Le Saux et al. 2000
SNPe6* E10/1299 G>T R433S 0.12 benign -3.59003 0 0 0 1.39 Conrad et al. 2002
SNPe7 E13/1684 C>T -- - 16.67 14.29 42.86 19.44 Oselin et al. 2003
SNPe8 E13/1704  C>T -- - 0 0 4.29 1.39
SNPe9* E14/1898 G>A R633Q 0.59 benign -0.6953 000 1 . 3 9 Le Saux et al. 2000
SNPe10 E16/2001 C>T - - - 000 1 . 3 9 Le Saux et al. 2000
SNPe11 E16/2007 C>T - - - 1.39 0 0 0
SNPe12* E16/2012 G>T G671V 0.00**
probably
damaging
-3.50442 0 0 1.43 2.78
Conrad et al. 2001;
Le Saux et al. 2000
SNPe13* E17/2168 G>A R723Q 0.36 benign -1.12171 02 . 8 60 0 Moriya et al. 2002
SNPe14 E17/2217 C>T - - - 00 1 . 4 3 0
SNPe15 E17/2268 G>A - - - 1.39 0 0 0
SNPe16* E20/2651 C>T T884M 0.13 benign - 0 1.43 0 0
SNPe17 E21/2793 C>T - - - 0 0 1.43 0
SNPe18 E28/4002 G>A - - - 8.33 7.14 20.00 37.50
Oselin et al. 2003;
Le Saux et al. 2000
SNP ID No. 
Minor allele frequency (%) Reference on functional
or association study
Polyphen SIFT
Amino acid
change
Panther
subPSEC
Extracellular
Cytoplasm
TM   1      2       3         4       5        6       7       8 9       10      11     12     13      14    15       16   17
MSD1 MSD2 MSD3
NBD1 NBD2BMC Genomics 2006, 7:111 http://www.biomedcentral.com/1471-2164/7/111
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likely to be selected against, resulting in their low frequen-
cies.
To assess if any of the non-synonymous SNPs at MRP1
have potentially damaging effect on the protein structure/
function, the location of these six SNPs were displayed on
the MRP1 protein topological image using the SOSUI and
TOPO2 programs. As evident in figure 2B, none of the
non-synonymous SNPs reside in the transmembrane
regions although four of these SNPs reside near or within
the nucleotide binding domain (NBD) of the MRP1 pro-
tein. Nonetheless, SNPe1 (SNP e2/218 C>T) and SNPe6
(SNP e10/1299G>T) reside near the transmembrane
region, while SNPe12 (SNP E16/2012 G>T) reside on a
conserved glycine residue near the conserved Walker A
consensus motif of the NBD [12], suggesting that these
SNPs may have functional significance. SNP e2/218 C>T
was only found at less than 3% in the Chinese and Malay
populations while SNP E10/1299 G>T occurred at less
than 2% in the Caucasian population only and SNP E16/
2012 G>T occurred at less than 3% in the Indian and Cau-
casian populations (Fig. 2C). The SNP frequencies of SNP
E10/1299 G>T and SNP E16/2012 G>T in the Caucasian
population were comparable to a previous report [12].
Three different algorithms, SIFT[46], Polymorphism Phe-
notyping (PolyPhen) [47]and PANTHER [48]were then
utilized to predict the functional significance of the six
non-synonymous SNPs. SIFT predicts the effect of amino
acid substitutions based on the assumption that the
important amino acid will be conserved in the protein
family[46]. PolyPhen predicts the effect of the amino acid
variant on the function or structure of the protein based
on current knowledge of protein structure, interactions
and evolution[47] while the PANTHER program predicts
the effect of an amino acid substitution on the protein's
function using amino acid substitution scores derived
from an alignment of related protein sequences and statis-
tics from hidden Markov models[48].
Interestingly, SNP E10/1299 G>T, which is located near
the transmembrane domain, was predicted to be poten-
tially deleterious by the PANTHER but not the SIFT or
PolyPhen algorithms. This SNP was reported to affect the
ability of MRP1 to confer drug resistance as well as to
transport organic anions [49] suggesting that the PAN-
THER program may be more accurate in predicting the
functional impact of polymorphisms than SIFT or
PolyPhen. This observation is similar to a previous report
that utilizes both bioinformatics and biochemical
approaches to compare the accuracy of the PolyPhen and
PANTHER programs in predicting functionally deleteri-
ous polymorphisms in the ABCA1 gene [50]. They found
that the PANTHER software is significantly (P < 0.05)
more accurate in its prediction of the functional conse-
quence of nonsynonymous SNPs. They also reported that
the PANTHER program is capable of correctly predicting
the functional impact of greater than 94% of the polymor-
phisms examined while PolyPhen is only ~88% accurate
in predicting the functional impact of polymorphisms
[50].
Significantly, all of the three different algorithms pre-
dicted that SNP E16/2012 G>T, which resides close to
Walker A and results in G671V substitution, was likely to
have a potentially deleterious effect on protein function
(Fig. 2C). The significance of this polymorphism has also
been demonstrated previously by Conrad et al. [12] who
reported that the mRNA expression of peripheral lym-
phocytes from individuals carrying the SNP E16/2012
G>T polymorphism was lower than the average expres-
sion level. The lower expression of the MRP1 G671V tran-
script is suggestive of greater accumulation of MRP1 drugs
in the cells which may lead to adverse drug reactions.
Curiously, that report also found that the G671V poly-
morphism did not affect the transport of MRP1 substrates
including leukotriene C4, 17β-estradiol 17β-(D)-glucuro-
nide and estrone sulfate by membrane vesicles prepared
from transiently transfected HEKSV293T cells [12].
Recently, the same group also reported similar MRP1 pro-
tein expression levels and transport properties in human
embryonic kidney cells were transfected with MRP1 con-
structs carrying either glycine or valine at amino acid posi-
tion 671 [51]. The observation that the G671V
polymorphism did not affect MRP1 protein expression or
transport ability of some MRP1 substrates in vitro [12,51]
does not rule out the possibility of functional significance
of this polymorphism in vivo especially since the same
group reported decreased transcript expression in individ-
uals carrying this polymorphism. It is still possible that
this polymorphism affect the transport of other MRP1
substrates that has not been examined. It is also possible
Table 6: Nucleotide diversity at MRP1
sequence section length(bp) SNPs θ* π* πNS/πS Tajima's D
Synonymous 1194 12 16.15 12.62 0.0743 -0.0209
Nonsynonymous 822 6 11.73 0.94 -0.0753
*Values of θ and π are listed as value × 104BMC Genomics 2006, 7:111 http://www.biomedcentral.com/1471-2164/7/111
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that although the SNP E16/2012 G>T polymorphism
does not affect MRP1 transport ability, it may affect other
yet-to-be-examined functional properties of the protein
(e.g. drug resistance capability or cellular anti-oxidative
defense or inflammation). It has been reported that an
artificial mutation E1089Q created in MRP1 markedly
affected the ability of MRP1 protein to confer resistance
without affecting its ability to transport organic anions
[52]. Hence, the SNP E16/2012 G>T polymorphism war-
rants further investigation.
Hence, the bioinformatics approach may be useful in
facilitating the prediction of potentially functionally sig-
nificant polymorphism so that future research may be
directed to characterizing these polymorphisms.
Functional implications of polymorphisms at MRP1
The current detailed characterization of polymorphisms
at MRP1 in four different ethnic populations highlights
several characteristics about this gene that may facilitate
more rational approaches to studies associating this gene
with functional changes. We have previously reported that
the diverse haplotypes and weak LD across MRP1
[20]could perhaps provide an explanation for the failure
of previous studies to detect association between poly-
morphisms in this gene and functional differences [12,17-
19] and highlight the importance of fully characterizing
the LD and haplotype profiles of the gene before embark-
ing on association studies. Its LD and haplotype architec-
ture suggest that it may be necessary to identify alternative
approaches for association studies of this gene as it may
not be feasible to utilize tag SNPs. A possible approach is
to identify polymorphisms with potential functional sig-
nificance before performing association studies, possibly
by identifying those polymorphisms that may have been
subjected to selection pressures.
We recently identified a high frequency SNP at the 5'
flanking promoter region of MRP1 that demonstrated evi-
dence of recent positive selection and affected the pro-
moter activity of MRP1[20]. In this report, through the
sequencing of the MRP1 exonic and flanking regions, we
identified a GCC-trinucleotide multi-allelic STR polymor-
phism residing within the 5'UTR/promoter region of
MRP1 that was found at relatively high frequencies in all
populations examined. Notably, the frequency distribu-
tion of the different number of STR alleles in the different
population was found to be different (Table 4). Although
it was previously reported that the 5'UTR/promoter region
contains the GCC-triplet repeats that is absent in the
rodent sequence and 7, 13 and/or 14 of these repeats were
observed in different cell lines and PBMC from a single
individual [7,53], no reports have yet examined the varia-
tion of this polymorphism in the different ethnic popula-
tions. This STR is approximately 296 bp from the SNP that
we previously reported to show evidence of recent positive
selection[20]. Given that the selection is recent it may be
expected that it would be in strong LD with the positively
selected SNP. Since STRs within/near promoters have
been implicated to affect promoter activity and expression
levels of the gene, it would be worthwhile to further exam-
ine the effect that this polymorphism together with the
positively selected SNP have in influencing promoter
activity and hence expression of MRP1.
Interestingly, while the promoter region of MRP1 may be
under recent positive selective pressure[20], in this study
we also found that the coding region of this gene may
have undergone negative selection pressure as suggested
by nucleotide diversity indices. Two coding SNPs E16/
2012 G>T and E10/1299 G>T have been predicted by
either the PANTHER program or all three programs (SIFT,
PolyPhen and PANTHER) to have a deleterious effect on
the structure/function of the protein. The significance of
these SNPs for general association studies may be limited
since these SNP occurs at very low frequencies (<3%) in
only one or two of the four populations examined. None-
theless, this SNP may be associated with rare events
including ADR.
Conclusion
In summary, based on the "common disease-common
variant" hypothesis, the previously reported common
polymorphism within the promoter of MRP1 that showed
evidence of recent positive selection [20]would be useful
for association studies of common diseases/drug
response. Nonetheless, the rare exonic SNP(s) in this gene
that we demonstrate here to be likely to be under negative
selection pressure may be useful for studies associating
this gene with rare phenotypes including ADR, which has
been listed as the top five leading causes of death in West-
ern countries [54].
Methods
Study population
The populations examined include individuals residing in
Singapore from the following ethnic groups: 36 Cauca-
sians and Chinese as well as 35 Malays and Indians. Race
and ethnic group were declared by the volunteers to be
true to three generations. Informed consent from the vol-
unteers and ethical approval from the National University
Hospital and the Changi General Hospital Institutional
Review Boards were obtained.
PCR and DNA sequencing
The MRP1 genomic DNA (NT_0101393.13) sequence was
obtained from GenBank [55] and used as the reference
sequence. For the sequencing of all 31 exons of MRP1, 30
pairs of primers (see Table 1) were designed using Vector
NTI 7.0 software and utilized to amplify these exons. TheBMC Genomics 2006, 7:111 http://www.biomedcentral.com/1471-2164/7/111
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amplicons spanned the entire exon as well as some flank-
ing sequences, to ensure that the splice donor and accep-
tor sites were also included. The PCR reaction was
performed in a 10 µl volume reaction containing 40 ng
genomic DNA template from the above mentioned sam-
ples, 5 µl 2 × PCR master mix buffer (Qiagen, Valencia,
CA, USA), with or without 1 µl Q-solution (depending on
the GC content of the amplicon) as well as 0.20 µM/L of
sense and anti-sense primers. PCR was carried out in a
GeneAmp® PCR System 9700 (Applied Biosystems, Foster
City, CA) with the thermal cycling conditions as follows:
an initial denaturation at 94°C for 15 min followed by 35
cycles at 94°C for 30 sec, temperature for the optimal
annealing of each amplicon as specified (Table 1) for 90
sec, and extension at 72°C for 60 sec. This was then fol-
lowed by a final elongation step at 72°C for 10 min. The
PCR products obtained were then treated with exonucle-
ase I and shrimp alkaline phosphatase (SAP, United States
Biochemical). Sequencing reactions were performed using
ABI PRISM Big Dye Terminator (V3.0) kit and the condi-
tions for the sequencing reactions were (for all the exons
except exon 1): 94°C for 15 min followed by 30 cycles at
96°C for 10 sec, 50°C for 5 sec and 60°C for 4 min. Due
to the high GC content of exon 1, the sequencing condi-
tions were modified as follows: 94°C for 15 min followed
by 35 cycles at 98°C for 30 sec, 48°C for 10 sec and 60°C
for 5 min. The final product was resolved by automated
capillary electrophoresis on an ABI PRISM 3700® DNA
analyzer (Applied Biosystems). The DNA sequence of
each exon obtained experimentally was then aligned
against the reference sequence (NT_0101393.13) using
the Vector NTI 7.0 software to identify the polymorphic
sites. Polymorphisms identified were verified through bi-
directional re-sequencing of all samples whose chromato-
grams do not clearly display the polymorphism as well as
randomly selected samples whose chromatograms clearly
show the polymorphism.
Population genetic parameters
Two common parameters of nucleotide diversity were cal-
culated: the neutral parameter (θ) which is the estimate of
population mutation parameter based on the number of
polymorphic sites in the samples [40] and nucleotide
diversity (π) which is the direct estimate of heterozygosity
per site, or the average proportion of nucleotides that dif-
fer between any randomly sampled pair of sequences
[40]. Each of these two parameters was calculated for syn-
onymous and nonsynonymous SNP sites. Tajima's D sta-
tistic was also calculated to assess deviations from the
neutral mutation model [41].
In Silico characterization of polymorphisms in exons
The programs Sorting Intolerant From Tolerant (SIFT)
[46], Polymorphism Phenotyping (PolyPhen) [47] and
PANTHER [48] were utilized to evaluate the potential
effect of amino acid substitutions resulting from the poly-
morphisms. Since the position of the non-synonymous
polymorphic amino acid residue on the MRP1 protein
may provide important clues with regards to its potential
functionality, the SOSUI program [56] was utilized to pre-
dict the topology of the MRP1 protein and the TOPO2
program [57] was used to display the location of the SNPs
on the MRP1 protein topological image.
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